STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 49.3 M

Revenue: As of FY2025 Q3, the actual value is USD 49.3 M.

EPS: As of FY2025 Q3, the actual value is USD -0.12.

EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.

Financial Metrics by Segment

Segment Revenue

• Total revenue for Q3 2025 was $49.3 million, a 36.7% increase from $36.1 million in Q3 2024. Excluding the Keystone acquisition, revenue increased by 29.0%.

Operational Metrics

• Net loss from continuing operations increased to - $9.7 million in Q3 2025 from - $5.6 million in Q3 2024, primarily due to a $5.2 million increase in realized loss from sales of short-term investments and a legal reserve.
• Gross profit for Q3 2025 was $9.5 million, up 75.9% from $5.4 million in Q3 2024. The gross margin improved to 19.4% from 15.0% in the prior year period.
• Adjusted EBITDA increased to $4.2 million in Q3 2025 from $0.1 million in Q3 2024, marking a significant improvement.
• Medical Segment Adjusted EBITDA rose by 93.5% to $7.6 million in Q3 2025, with the margin increasing to 15.3% from 10.8% in Q3 2024.

Cash Flow

• Operating cash flow was - $37.3 million in Q3 2025, impacted by $44.3 million of Keystone acquisition consideration included in operating cash flow.
• Free cash flow from continuing operations was $1.9 million in Q3 2025, excluding acquisition consideration and transaction costs.

Unique Metrics

• No unique company-specific financial indicators were mentioned in the reference.

Outlook / Guidance

• Strata Critical Medical raised its 2025 revenue guidance to $185-195 million and reaffirmed its Adjusted EBITDA guidance of $13-14 million.